BORTIVA
Description
Bortezomib is the first of its class to be approved for clinical use. It is a 26S proteosome inhibitor (26S proteosome is the principal regulator of the intracellular protein degradation that helps in cell proliferation and survival regulation).
Indications:
- For the treatment of patients with multiple myeloma
- For the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy
| Generic Name | Strength | Standard | Type | Packing | Pack Size |
| Bortezomib | 2 mg / 3.5mg | USP | INJ | Vial | 1 Vial |